Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. / Gudbergsson, Johann Mar; Christensen, Esben; Kostrikov, Serhii; Moos, Torben; Duroux, Meg; Kjær, Andreas; Johnsen, Kasper Bendix; Andresen, Thomas Lars.
In: Molecular Neurobiology, Vol. 57, No. 9, 2020, p. 3943-3955.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations
AU - Gudbergsson, Johann Mar
AU - Christensen, Esben
AU - Kostrikov, Serhii
AU - Moos, Torben
AU - Duroux, Meg
AU - Kjær, Andreas
AU - Johnsen, Kasper Bendix
AU - Andresen, Thomas Lars
PY - 2020
Y1 - 2020
N2 - Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.
AB - Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.
KW - Cancer
KW - CD133
KW - CD44
KW - Glioblastoma
KW - Plasticity
KW - Population
KW - Resistance
KW - Stem cells
KW - Subpopulation
KW - Treatment
KW - Tumor
U2 - 10.1007/s12035-020-02004-2
DO - 10.1007/s12035-020-02004-2
M3 - Journal article
C2 - 32632605
AN - SCOPUS:85087620550
VL - 57
SP - 3943
EP - 3955
JO - Molecular Neurobiology
JF - Molecular Neurobiology
SN - 0893-7648
IS - 9
ER -
ID: 246868965